Top-Rated StocksTop-RatedNASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $109.90 -0.96 (-0.87%) (As of 12:15 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Sarepta Therapeutics Stock (NASDAQ:SRPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sarepta Therapeutics alerts:Sign Up Key Stats Today's Range$109.03▼$110.8750-Day Range$104.54▼$132.0252-Week Range$78.67▼$173.25Volume301,364 shsAverage Volume1.23 million shsMarket Capitalization$10.50 billionP/E Ratio87.92Dividend YieldN/APrice Target$181.33Consensus RatingBuy Company OverviewSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More… My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Sarepta Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks98th Percentile Overall ScoreSRPT MarketRank™: Sarepta Therapeutics scored higher than 98% of companies evaluated by MarketBeat, and ranked 26th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingSarepta Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 20 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth438.65% Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 438.65% in the coming year, from $2.07 to $11.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is 88.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is 88.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 87.86.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 8.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.86% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 1.06%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.65 Percentage of Shares Shorted5.86% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 1.06%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment0.69 News SentimentSarepta Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Sarepta Therapeutics this week, compared to 10 articles on an average week.Search Interest42 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $822,100.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Stock News HeadlinesBuy Rating on Sarepta Therapeutics: Confidence in Elevidys’ Market Potential and Strategic ExpansionNovember 21 at 8:42 AM | markets.businessinsider.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Buy" by BrokeragesNovember 17, 2024 | americanbankingnews.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…November 21, 2024 | Colonial Metals (Ad)Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy NowNovember 15, 2024 | msn.comJanus Henderson Group PLC's Strategic Acquisition in Sarepta Therapeutics IncNovember 14, 2024 | gurufocus.comWhy Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They SeemNovember 14, 2024 | finance.yahoo.comSarepta recent weakness brings buying opportunity, says JPMorganNovember 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and DocGo (DCGO)November 11, 2024 | markets.businessinsider.comSee More Headlines SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $96.43 at the beginning of 2024. Since then, SRPT shares have increased by 15.0% and is now trading at $110.86. View the best growth stocks for 2024 here. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) posted its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The company's revenue was up 38.9% on a year-over-year basis. Does Sarepta Therapeutics have any subsidiaries? Sarepta Therapeutics subsidiaries include these companies: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' top institutional investors include Janus Henderson Group PLC (4.56%), Wellington Management Group LLP (2.85%), Geode Capital Management LLC (1.78%) and Jacobs Levy Equity Management Inc. (0.79%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Kathryn Jean Boor, Stephen Mayo and Louise Rodino-Klapac. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN). Company Calendar Last Earnings8/07/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/26/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$181.33 High Stock Price Target$230.00 Low Stock Price Target$109.00 Potential Upside/Downside+63.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage22 Analysts Profitability EPS (Most Recent Fiscal Year)$1.25 Trailing P/E Ratio88.69 Forward P/E Ratio53.56 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins7.43% Pretax Margin7.89% Return on Equity11.00% Return on Assets3.35% Debt Debt-to-Equity Ratio0.93 Current Ratio3.84 Quick Ratio3.03 Sales & Book Value Annual Sales$1.64 billion Price / Sales6.46 Cash FlowN/A Price / Cash FlowN/A Book Value$9.19 per share Price / Book12.06Miscellaneous Outstanding Shares95,520,000Free Float88,165,000Market Cap$10.59 billion OptionableOptionable Beta0.81 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:SRPT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.